• Changing Lives

    We created our antibody-drug conjugate (ADC) technology to achieve better therapies for people with cancer. It is used in Roche's Kadcyla®, which is making a difference for people today.

    Learn More
  • Changing Lives

    Our work changes us - enabling us to use our special skills and expertise to achieve new therapies for people with cancer.

  • Changing Lives

    A growing number of compounds with our technology are being evaluated in the clinic to treat many different types of cancer.

News & Events

Maytansinoid ADCs and Checkpoint Inhibition

Read More

FORWARD I and FORWARD II clinical trials of mirvetuximab soravtansine are open for enrollment.

Read More

Encouraging clinical data reported at World Conference on Lung Cancer with anetumab ravtansine (BAY 94-9343) in mesothelioma.

Read More

ImmunoGen, Inc. one of The Boston Globe's
Top Places to Work - recognized for third

consecutive year

Read More

Top Places to Work

Clinical Trial

Clinical trials can provide an opportunity for appropriate patients to receive experimental therapies. Several trials with ImmunoGen ADCs are currently enrolling patients.

Learn More

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue